Cisplatin Plus Research Articles

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

BackgroundBiliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1–3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarkable risk of postoperative morbidity and mortality, the 5-year survival rate after radical surgery (R0) is 20–40% and recurrence rates are up to ~ 75%(4–6). Up to ~ 40% of patients relapse within 12 months after resection, and half of these patient will recur systemically(4–6). There is no standard of care for neoadjuvant chemotherapy (NAC) in resectable BTC, but retrospective reports suggest its potential benefit (7, 8).MethodsPURITY is a no-profit, multicentre, randomized phase II/III trial aimed at evaluating the efficacy of the combination of gemcitabine, cisplatin and nabpaclitaxel (GAP) as neoadjuvant treatment in patients with resectable BTC at high risk for recurrence. Primary objective of this study is to evaluate the efficacy of neoadjuvant GAP followed by surgery as compared to upfront surgery, in terms of 12-month progression-free survival for the phase II part and of progression free survival (PFS) for the phase III study.Key Secondary objectives are event free survival (EFS), relapse-free survival, (RFS), overall survival (OS), R0/R1/R2 resection rate, quality of life (QoL), overall response rate (ORR), resectability. Safety analyses will include toxicity rate and perioperative morbidity and mortality rate.Exploratory studies including Next-Generation Sequencing (NGS) in archival tumor tissues and longitudinal ctDNA analysis are planned to identify potential biomarkers of primary resistance and prognosis.DiscussionConsidering the poor prognosis of resected BTC experiencing early tumor recurrence and the negative prognostic impact of R1/R2 resections, PURITY study is based on the rationale that NAC may improve R0 resection rates and ultimately patients’ outcomes. Furthermore, NAC should allow early eradication of microscopic distant metastases, undetectable by imaging but already present at the time of diagnosis and avoid mortality and morbidity associated with resection for patients with rapid progression or worsening general condition during neoadjuvant therapy. The randomized PURITY study will evaluate whether patients affected by BTC at high risk from recurrence benefit from a neoadjuvant therapy with GAP regimen as compared to immediate surgery.Trial registrationPURITY is registered at ClinicalTrials.gov (NCT06037980) and EuCT(2023–503295-25–00).

Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.

The results reported in the TOPAZ-1 phase III trial led to the approval of the combination of cisplatin and gemcitabine with durvalumab as the new first-line standard of care for patients with locally advanced or metastatic cholangiocarcinoma. We performed a clustering analysis to classify patients into different groups based on their mutation profile, correlating the results of the analysis with clinical outcomes. We selected 51 patients with cholangiocarcinoma who were treated with the combination of chemotherapy and durvalumab and who were screened usingthe next-generation sequencing-based FoundationOne gene panel. We conducted mutation-based clustering of tumors and a survival analysis. Three main clusters were identified. Cluster 1 is mostly characterized by mutations in genes belonging to the chromatin modification pathway, altered in 100% of patients. Cluster 2 is characterized by the alteration of several pathways, among which DNA damage control, chromatin modification, RTK/RAS, cell-cycle apoptosis, TP53, and PI3K were the most affected. Finally, most altered pathways in cluster 3 were RTK/RAS and cell-cycle apoptosis. Overall response rate was 4/13 (31%), 12/24 (50%), and 0/10 (0%) in cluster 1, cluster 2, and cluster 3, respectively, and the difference between the three clusters was statistically significant (p = 0.0188). By grouping patients into three clusters with distinct molecular and genomic alterations, our analysis showed that patients included in cluster 2 had higher overall response rates, whereas patients included in cluster 3 had no objective response. Further investigations on larger and external cohorts are needed in order to validate our results.

Flashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung Cancer

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. May 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02804 Journal of Clinical Oncology - published online before print May 5, 2023 PMID: 37146425 Flashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung Cancer Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Duke Cancer Institute, Division of Medical Oncology, Durham, NC2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02804 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYThis phase III, noninferiority study1 investigated the novel chemotherapy combination of cisplatin and pemetrexed compared with the standard combination of cisplatin and gemcitabine demonstrating that survival was noninferior between the two platinum-based combinations, and a lower rate of grade 3 or 4 neutropenia and febrile neutropenia was observed with cisplatin and pemetrexed. However, cisplatin and pemetrexed demonstrated a superior survival in patients with adenocarcinoma and large cell histologies and inferior survival in patients with squamous histology, and after this trial, the use of pemetrexed was restricted to patients with nonsquamous histology.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Icotinib versus Cisplatin Plus Docetaxel as Adjuvant Chemotherapy in Patients with Stage II (N1+) Non-Small Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.

PurposeThe superior efficacy of first-line treatment with icotinib over that of standard chemotherapy has been well demonstrated in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation. However, whether icotinib is superior to cisplatin plus docetaxel as adjuvant chemotherapy in patients with stage II (N1+) NSCLC selected by EGFR mutation is controversial.MethodsA total of 43 patients with completely resected stage II (T1-2N1M0) NSCLC and proven sensitive EGFR mutation (19Del or L858R) between January 2010 and December 2019 were included in our study. The disease-free survival (DFS) and overall survival (OS) were analyzed in 22 patients treated with icotinib and 21 patients treated with cisplatin plus docetaxel. Factors affecting DFS and OS were assessed by the Kaplan-Meier (KM) estimator and univariate Cox regression analysis.ResultsOur cohort included 22 icotinib patients and 21 cisplatin plus docetaxel patients with a median follow-up of 35.5 months and 38 months, respectively. Survival time was significantly longer in the icotinib group than in the chemotherapy group, with a median DFS of 47 months (95% CI, not reached) versus 18 months (95% CI, 12.4–23.6; HR 0.16; 95% CI, 0.07–0.35; log-rank p<0.0001). In the icotinib group, the most common adverse effects (AEs) were skin rash (40.9%) and elevated alanine aminotransferase (22.7%), whereas in the cisplatin plus docetaxel group, the most common AEs were nausea or vomiting (90.5%), anorexia (71.4%), and fatigue (71.4%). No deaths were treatment-related.ConclusionIn this study, we demonstrated that in EGFR mutation-positive patients with completely resected stage II (T1-2N1M0) NSCLC, icotinib might provide DFS benefits, and reduced drug toxicity compared to cisplatin plus docetaxel. Thus, icotinib may be a reasonable option for adjuvant chemotherapy in patients with pathological stage II (N1+) NSCLC with EGFR mutation.

Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types)

Objective:To evaluate the response rate of Cisplatin plus Docetaxel in the treatment of locally advanced head and neck squamous cell carcinomas (HNSCC) at a tertiary care hospital in Karachi, Pakistan. Materials and Methods:It was a longitudinal study, conducted at the Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan from December 2018 to June 2019. One hundred patients of age 14-66 years of age of either gender with histologically proven Squamous Cell Carcinoma of Head and Neck, Stage III and IV (locally advanced) with no distant metastases were included in the study. Patients who were declared unresectable by the otolaryngologist and those with delayed appointment for radiation were given 3 cycles of Induction Chemotherapy with Cisplatin and Docetaxel, both at a dose of 75mg/m2 3 weekly. After 3 cycles, CT scan was repeated to assess the clinical response. Those patients who had partial or complete response as per RECIST criteria were re-assessed by the otolaryngologist and were planned for surgery if disease became resectable while other patients were referred for Concurrent Chemo-Radiation Therapy (CCRT). SPSS version 23 was used to analyze data. Results:The partial response was achieved in majority of the patients after Induction Chemotherapy with Docetaxel and Cisplatin (62%) with a complete response in 12 %. However, 22% showed progression of the disease, and 4% showed stable disease. The most frequent side effects observed were diarrhea (62%) and neutropenia (57%). Conclusion:Induction chemotherapy with Cisplatin and Docetaxel is a promising regimen with good response and favorable toxicity profile and can be considered as a potentially effective outpatient regimen for locally advanced squamous cell carcinoma of head and neck.

ES02.01 Biomarker Testing in LA Disease

ES02.01 Biomarker Testing in LA Disease

A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302

Background: There has been no study so far on gemcitabine continuous maintenance therapy targeting only squamous non-small-cell lung cancer (NSCLC) patients. This study aimed to assess the efficacy and safety of cisplatin plus gemcitabine followed by maintenance gemcitabine for chemotherapy- naïve Japanese patients with advanced squamous NSCLC. Methods: The patients received 4 cycles of gemcitabine (1,000 mg/m², days 1 and 8) and cisplatin (80 mg/m², day 1) every 3 weeks, followed by gemcitabine alone as maintenance therapy every 3 weeks until disease progression or unacceptable toxicity. The primary end point of the study was progression-free survival (PFS) from the date of registration. Results: From May 2013 to October 2018, 26 patients were enrolled, and 25 patients received ≥1 cycle of planned treatment. Eighteen patients (69.2%) received 4 cycles of cisplatin plus gemcitabine, and 16 patients (61.5%) received ≥1 cycle of maintenance gemcitabine. The median PFS from the date of registration was 5.3 months (95% CI 2.9–7.3 months). In 16 patients who received ≥1 cycle of maintenance gemcitabine, the median PFS from the date of maintenance gemcitabine initiation was 3.8 months (95% CI 2.3–5.2 months). Their median overall survival from the date of registration was 11.9 months (95% CI 7.5–26.5 months). During the maintenance therapy, adverse events (AEs) were mostly Common Terminology Criteria for AE grade 1. Conclusions: While this trial did not meet the primary endpoint, the sufficient efficacy and feasibility of gemcitabine maintenance therapy were suggested.

The Prognostic Nutrition Index Predicts the Development of Hematological Toxicities in and the Prognosis of Esophageal Cancer Patients Treated with Cisplatin Plus 5-Fluorouracil Chemotherapy

ABSTRACTThe prognostic nutrition index (PNI), calculated based on serum albumin and lymphocyte counts, predicts the prognosis of several cancers, including operated esophageal cancers. In this study, we determined whether PNI could predict the occurrence of severe adverse events by chemotherapy and chemoradiotherapy, and overall survival in esophageal cancer. We collected data from 191 patients with esophageal cancer treated with at least one course of cisplatin and 5-fluorouracil from 2005 to 2016. We compared the incidences of severe adverse events and overall survival between a high- and a low-PNI group. The optimal cut-off value of the Onodera PNI was 43.2. Patients with low PNIs suffered more frequent severe adverse events than did those with high PNIs, and the latter patients survived longer. The PNI was independently prognostic of overall survival and stage. The PNI predicted the development of severe adverse events caused by chemotherapy or chemoradiotherapy, and overall survival, in esophageal cancer patients.

ED08.04 Perspectives of Targeted Therapies and Immunotherapy in Completely Resected NSCLC

ED08.04 Perspectives of Targeted Therapies and Immunotherapy in Completely Resected NSCLC

Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer

We report a subgroup analysis primarily focused on human papillomavirus (HPV)-related oropharyngeal cancer (OPC) from the Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT; ClinicalTrials.gov identifier NCT01216020) trial comparing radiation therapy with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced head and neck cancer. The data from all the patients in the CTXMAB+RT trial were reviewed and separately analyzed in 3 groups: p16-positive OPC, p16-negative OPC, and all other cancer sites. The endpoints of interest were locoregionalcontrol (LC), metastasis-free survival, cancer-specific survival (CSS), and overall survival (OS). Severe and fatal infectious complications were also reanalyzed to more thoroughly investigate the association between CTX treatment and potentially life-threatening reactions. A total of 33 patients had OPC. The HPV status was available for 30 of the 33 patients. Thus, 3 patients treated with CDDP but with unknown HPV status were excluded from the survival analysis. The small number of patients in each group did not allow for significance to be reached for any of the outcomes analyzed. A trend favored the CDDP arm in the p16-positive group for the 2-year LC and OS/CSS rates (100% vs 72.9% and 100% vs 77.8% for CDDP vs CTX). In this group of patients, the hazard ratio for the treatment arm (CTX vs CDDP) was 4.7 (95% confidence interval [CI] 0.5-40.3) for LC, 3.4 (95% CI 0.4-30.5) for OS, and 2.4 for CSS (95% CI 0.2-23.2). A survival benefit favoring the CDDP arm was not evident in the p16-negative OPC group or for patients with cancer located in other sites. Serious or fatal infectious complications occurred only in the CTX arm. In patients with p16-positive OPC in the CTXMAB+RT trial, CTX had lower efficacy than CDDP, with possible implications for treatment selection in this clinical setting.

Phase 2 Study of Neoadjuvant Chemoradiation Therapy With Cisplatin Plus 5-Fluorouracil and Elective Nodal Irradiation Followed by Surgery for Stage II/III Esophageal Squamous Cell Carcinoma

Phase 2 Study of Neoadjuvant Chemoradiation Therapy With Cisplatin Plus 5-Fluorouracil and Elective Nodal Irradiation Followed by Surgery for Stage II/III Esophageal Squamous Cell Carcinoma

USANZ and TROG Inter-group Phase 3 Trial (TROG 02.03) Concurrent Weekly Cisplatin Plus Radiation Therapy in Localized Muscle Invasive Bladder Cancer: Compliance< Toxicity< Quality of Life and Overall Results

This phase III trial investigated combination of weekly cisplatin and radiation therapy compared with radiation therapy (RT) alone in the definitive treatment of localised muscle-invasive bladder cancer. The investigative arm was adopted from our previous phase II studies (TROG 97.01 and 99.06). Eligible adult patients with localized Stage T2-T4a, non-bulky (< 7 cm in maximum dimension) bladder cancer of predominant transitional cell carcinoma histology were randomized (1:1) to receive either definitive 3 D conformal RT to the bladder (64Gy/32fractions) alone or concurrently with weekly cisplatin (35mg/m2).The main exclusion criteria were: presence of extensive/ multifocal carcinoma in situ, significantly reduced bladder capacity and any contraindications to the use of pelvic RT or cisplatin chemotherapy. An initial maximal transurethral resection of the bladder tumour preceded randomisation.The primary outcome was local failure at 3 years. Secondary endpoints included complete response rate at 3 months, disease free and overall survival (DFS and OS), patterns of failure, acute and late toxicity and Quality of life (QOL). QOL was measured using the EORTC QLC-C30 and bladder cancer (QLQ-BLM30) modules. QOL aspect of definitive therapy has previously not been investigated in a Phase III study. To determine the sample size the 3 year local failure rate with RT was estimated to be 70% and that with chemoradiation therapy to be 45%. To demonstrate this difference between the 2 arms with 80% power and 95% confidence it was estimated that 138 patients would be required. Allowing for a loss of 5-10% of patients to analysis the accrual target was set at 150 patients over 4 years. Slow accrual lead the trial to be closed after only 68 patients were randomised. The majority of patients were > 70 years old and or had significant co-morbidities. Compliance with RT overall was excellent. About15% of patients in the chemoradiation arm required a significant reduction in cisplatin dose delivery mainly because of declining renal function. Acute and late toxicity was similar in the two arms, but chemoradiation had a greater impact on QOL. Recovery however did follow and the improved bladder QOL was maintained in surviving patients. Notwithstanding the small sample size, in terms of local failure rates and other tumour specific end points interesting trends have emerged in favour of the chemoradiation therapy. Whilst weekly cisplatin chemoradiation in this challenging group of patients has an acceptable acute toxicity profile, it has the potential to impact on Qol .The domains affected do recover with satisfactory bladder function being sustained. The regimen also holds promise in terms of potential to improve local control, DFS and OS.

A Randomized Phase Ii Trial of Cisplatin Plus Gemcitabine Versus Carboplatin Plus Gemcitabine in Patients with Completely Resected Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (Hot0703)

ABSTRACT Aim: The combination of platinum and gemcitabine (GEM) (P/G) is one of the most beneficial regimens in advanced non-small cell lung cancer (NSCLC). This study aimed to evaluate the efficacy and safety of P/G in adjuvant chemotherapy of postoperative NSCLC and select the P/G arm for a phase III trial. Methods: Patients with postoperative stage IB-IIIA NSCLC were randomly assigned to either cisplatin (CDDP) 40 mg/m2 on days 1 and 8 plus GEM 1000 mg/m2 on days 1 and 8 (GP arm) or carboplatin (CBDCA) AUC 5 on day 8 plus GEM 1000 mg/m2 on days 1 and 8 (GC arm) every 3 weeks for 4 cycles. The primary endpoint was 2-year disease-free survival (DFS); secondary endpoints were safety, feasibility, overall survival (OS), and biomarker analyses. Results: 102 patients were randomized (stages: 22% IB, 36% II, 42% IIIA; histology: 74% adenocarcinoma, 26% non-adenocarcinoma). Thirty-seven (73%) of 51 patients in each arm completed 4 cycles. Compliance was greater with GP than GC (dose intensity 87.6% vs. 77.9%, respectively; P Conclusions: Both P/G combination regimens were feasible and well-tolerated and, thus, may be potential options for adjuvant treatment in postoperative NSCLC. Although there were no significant differences in DFS between the two regimens, the data presented favor adopting GC for further evaluation. Disclosure: All authors have declared no conflicts of interest.

Cisplatin Plus Etoposide in the Adjuvant Treatment of Patients with Non-Small Cell Lung Cancer

Cisplatin Plus Etoposide in the Adjuvant Treatment of Patients with Non-Small Cell Lung Cancer

進行期非扁平上皮非小細胞肺癌に対する初回治療でのcisplatin+pemetrexed使用症例の臨床的検討

目的．未治療非小細胞肺癌に対するcisplatin（CDDP)+pemetrexed（PEM）併用療法の効果と忍容性を検討した．方法．当科でCDDP+PEM併用療法を行った未治療非扁平上皮非小細胞肺癌41例（男性31例，女性10例）を対象に後方視的検討を行った．結果．年齢中央値は66歳（44～78歳）．組織型は腺癌39例，非扁平上皮非小細胞癌2例．Grade 3/4の有害事象は白血球減少12.2％，好中球減少34.1％，貧血7.3％，血小板減少4.9％，低ナトリウム血症24.4％，食思不振22.0％，嘔気9.8％，嘔吐2.4％であった．治療効果は奏効率が35.3％，病勢制御率が76.5％であり，median progression-free survivalは5.2ヵ月，median survival timeは22.1ヵ月であった．結論．CDDP+PEM併用療法について，本結果は大規模臨床試験と同等の治療効果を認めた．しかし消化器毒性が多く，嘔気の管理が重要と思われた．また，低ナトリウム血症が多かった．

O1–043 - Second-Line Therapy of S-1 for Patients with Advanced Biliary Tract Cancer After Failure to Cisplatin Plus Gemcitabine

O1–043 - Second-Line Therapy of S-1 for Patients with Advanced Biliary Tract Cancer After Failure to Cisplatin Plus Gemcitabine

PCN101 - A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden

PCN101 - A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden

Efficacy of Concomitant Cisplatin Plus Radiation Therapy and High-Dose-Rate Brachytherapy Versus Radiation Therapy Alone for Stage IIIB Epidermoid Cervical Cancer: A 10-Year Randomized Controlled Trial

Efficacy of Concomitant Cisplatin Plus Radiation Therapy and High-Dose-Rate Brachytherapy Versus Radiation Therapy Alone for Stage IIIB Epidermoid Cervical Cancer: A 10-Year Randomized Controlled Trial

Cisplatin Plus Gemcitabine for Treatment of Breast Cancer Patients with Brain Metastases: a Preferential Option for Triple Negative Patients?

To assess the efficacy and tolerability of Cisplatin plus Gemcitabine combination in patients with brain metastases (BM) from breast cancer (BC). Eighteen BC patients with BM who were treated with Cisplatin plus Gemcitabine regimen between 2003-2011 were evaluated. A median of 6 cycles of this regimen were received, in fifteen patients (83.3%) as first-line chemotherapy, in 2 as second- line and in 1 as third-line after diagnosis of BM. Dose reduction was performed in 11 (61.1%) patients; major reasons were neutropenia and leukopenia. Grade III neutropenia and Grade II trombocytopenia rates were 33.3% and 16.7% respectively. Overall response rate (ORR; complete+partial response rate) was 33.4% (n=6) for the entire study population; triple negative patients achieved an 66.6% ORR while hormone receptor (HR) positive patients had 25% and HER2 positive patients 12.5%. Median progression-free survival was 5.6 months (2.4-8.8 months, 95%CI) and longer in patients with triple negative breast cancer (TNBC) (median 7.4 months, 95%CI, 2.4-12.3 months) than the patients with other subtypes (median 5 months for HER2 positive and 3.6 months for HR positive patients). Median PFS of the patients with TNBC who received this regimen as first-line was 9.2 months (5.2-13.2 months, 95%CI). Cisplatin plus Gemcitabine may be a treatment option for patients with BM from breast cancer. Longer PFS and higher response rates are results that support the usage of this regimen especially for the triple negative subtype. However, further prospective and randomized trials are clearly required to provide more exact information.

P-0126 - Prognosis Predicting Factors in Patients with Intrahepatic or Hilar Cholangiocarcinoma Who Received Cisplatin Plus Gemcitabine Chemotherapy

P-0126 - Prognosis Predicting Factors in Patients with Intrahepatic or Hilar Cholangiocarcinoma Who Received Cisplatin Plus Gemcitabine Chemotherapy